Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polyethylene glycol modified polypeptide for inhibiting tumor necrosis factor-alpha and application of polypeptide

A technology of tumor necrosis factor and polyethylene glycol, applied to non-active ingredient medical preparations, active ingredient-containing medical preparations, peptides, etc., to achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2014-04-23
罗瑞雪
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
The research on PEG modification of synthetic small molecule peptides started late, but it has attracted the attention of many researchers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] In vivo immune protection of polyethylene glycol-modified tumor necrosis factor-α polypeptide in mice with collagen-induced arthritis

[0020] To construct a collagen-type mouse arthritis animal model, and to study the therapeutic effect of polyethylene glycol-modified anti-tumor necrosis factor-α polypeptide on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, body weight 18-22 g, were randomly divided into 6 groups, namely normal control group, model control group, peptide inhibitor 1 low, middle and high dosage groups (5, 10 , 20 mg / kg) and positive drug control group (methotrexate 2 mg / kg). In addition to the normal group, the mouse CIA model was established in each experimental group on day 0 by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a...

Embodiment 3

[0025] Polyethylene glycol-modified anti-tumor necrosis factor-α polypeptide protects the immune system in an adjuvanted rat arthritis model in vivo

[0026]To construct an adjuvant rat arthritis animal model, and study the therapeutic effect of polyethylene glycol-modified anti-tumor necrosis factor-α polypeptide on adjuvant arthritis (Adjuvant arthritis, AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008 -0016), male, with a body weight of 140 g-160 g, were randomly divided into 6 groups, namely normal control group, model control group, PEG-modified anti-tumor necrosis factor-α polypeptide low, medium and high dosage groups (5 , 10, 20 mg / kg) and positive drug control group (methotrexate 1 mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inact...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicaments, and in particular relates to polypeptide capable of inhibiting a tumor necrosis factor-alpha and preventing and treating rheumatoid arthritis. The polypeptide is modified by polyethylene glycol and the sequence of the polypeptide, namely mPEG-SC10k-Pro-Thr-Met-Ser-Trp, is a brand-new sequence. The polypeptide disclosed by the invention has the beneficial effects of being capable of treating rheumatoid arthritis and having potential value on development of new medicaments.

Description

Technical field: [0001] The invention involves the drug field, which specifically involves the inhibitory tumor necrosis factor-α polypeptide for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] RHEUMATOID Arthritis (RA) is one of the most common clinical inflammatory arthriology and major disabled factors.There are about 0.5%-1.0%in the world, and the onset of RA is about 0.4%in my country.RA can occur at any age, and the incidence increases with age.The age of women is 45-55 years old. Gender is closely related to RA. The ratio of men and women is about 1: 3.RA is a chronic systemic inflammatory disease that has not yet been understood. It is the main clinical manifestation with chronic, symmetrical, polymeric membrane arthritis and arthritic pathogens, and belongs to autoimmune inflammatory diseases.Patients often take the pain and swelling of the hand or wrist (especially the swelling of the back of the wrist) as the first symptom. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K38/08A61K47/48A61P19/02A61P29/00
Inventor 罗瑞雪
Owner 罗瑞雪
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com